investors
investors
AI transforming biotechnology: From form with...
Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states: "The Large Language...
investors
Introducing our new CCO: Damien Perriman
Our new Chief Commercial Officer, Damien Perriman, brings more than two decades of experience in...
investors
CNBC closing bell footage from Feb 19, 2025
Part of the coverage of eXoZymes’ closing bell ceremony on Feb 19, 2025 from CNBC. Credit: CNBC...
investors
Nasdaq: eXoZymes CEO Michael Heltzen's closing...
This Michael Heltzen's (CEO of eXoZymes) closing bell speech from February 19, 2025, when...
investors
Looking at the rest of 2025 - part 4 of a...
In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne...
investors
Go To Market Strategy - part 3 of a fireside...
In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne...
investors
Using AI for Enzyme Engineering - part 2 of a...
In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne...
investors
Looking back at 2024 - part 1 of a fireside...
In this video - recorded on Dec 29, 2024 - Lou Basenese interviews Michael Heltzen about going...
investors
Invizyne IPO comments by CEO Michael Heltzen
Today's Nasdaq IPO marks new era of biomanufacturing - pioneered by Invizyne's breakthrough...
investors
Dr. Lalonde: From two years and 25 scientists...
Dr. Lalonde: From two years and 25 scientists to a few scientists for a few months "When I...